Clinical test may predict best rheumatoid arthritis biologic for each individual
A clinical test to predict the best rheumatoid arthritis (RA) biologic for each individual could revolutionize personalized medicine in rheumatology. While no universally validated test exists yet, several promising approaches are being explored:
1. Biomarker-Based Prediction
Researchers are investigating biomarkers that may predict response to specific biologics, such as:
- Anti-CCP antibodies & RF status: May influence response to rituximab (anti-CD20) or TNF inhibitors.
- Gene expression profiles: Certain immune signatures (e.g., interferon-high vs. IL-6-driven) may favor JAK inhibitors (tofacitinib, baricitinib) or IL-6 blockers (tocilizumab).
- Serum cytokine levels: High IL-6 may predict better response to tocilizumab, while TNF-α dominance may favor TNF inhibitors (adalimumab, infliximab).
2. Genetic & Pharmacogenomic Testing
- HLA-DRB1 shared epitope: May predict response to TNF inhibitors.
- Fcγ receptor polymorphisms: Could influence response to rituximab.
- GWAS (Genome-Wide Association Studies): Identifying genetic variants linked to drug metabolism and efficacy.
3. Machine Learning & AI Models
- Algorithms analyzing electronic health records, lab data, and imaging to predict optimal biologics.
- PRECISE-RA (Precision Medicine in RA) and other trials are testing AI-driven decision tools.
4. Synovial Tissue Analysis (Emerging)
- Biopsy-driven profiling of joint inflammation (e.g., B-cell vs. macrophage dominance) may guide therapy (e.g., rituximab for B-cell-rich synovitis).
Current Limitations & Future Outlook
- No single test is FDA-approved for RA biologic selection yet.
- Trial-and-error remains common, but multi-omics approaches (genomics, proteomics, metabolomics) may soon enable precision prescribing.
Reference:
https://pmc.ncbi.nlm.nih.gov/articles/PMC10654285
https://www.sciencedirect.com/science/article/pii/S0049017223001713
Medications that have been suggested by doctors worldwide are available on below link